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Abstract
Peptidylarginine deiminase IV (PADI4) catalyzes the conversion of positively charged arginine and methylarginine residues
to neutrally charged citrulline, and this activity has been linked to the repression of a limited number of target genes. To
broaden our knowledge of the regulatory potential of PADI4, we utilized chromatin immunoprecipitation coupled with
promoter tiling array (ChIP-chip) analysis to more comprehensively investigate the range of PADI4 target genes across the
genome in MCF-7 breast cancer cells. Results showed that PADI4 is enriched in gene promoter regions near transcription
start sites (TSSs); and, surprisingly, this pattern of binding is primarily associated with actively transcribed genes.
Computational analysis found potential binding sites for Elk-1, a member of the ETS oncogene family, to be highly enriched
around PADI4 binding sites; and coimmunoprecipitation analysis then confirmed that Elk-1 physically associates with PADI4.
To better understand how PADI4 may facilitate gene transactivation, we then show that PADI4 interacts with Elk-1 at the c-
Fos promoter and that, following Epidermal Growth Factor (EGF) stimulation, PADI4 catalytic activity facilitates Elk-1
phosphorylation, histone H4 acetylation, and c-Fos transcriptional activation. These results define a novel role for PADI4 as a
transcription factor co-activator.
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Introduction
The mitogen activated protein kinase/extracellular signal-
related kinase (MAPK/ERK) pathway couples extracellular
signals with a range of intracellular responses including cell
growth, proliferation, and differentiation. An important target of
MAPK/ERK activity is Elk-1 (Ets-like protein-1), a member of the
ternary complex factors family of ETS domain transcription
factors [1]. The ternary complex factors form a complex with
serum response factor at the serum response element (SRE) and
this cis-element is required for regulation of many immediate-early
genes by stimulation with growth factors, such as EGF [2–6]. Elk-1
is activated by MAPK/ERK via phosphorylation of serine
residues 383 and 389 within the transactivation domain [7,8],
leading to an enhanced association between Elk-1 and the histone
actyltransferase (HAT), p300 [9]. The activated Elk-1-p300
complex then induces a strong p300-mediated acetyltransferase
activity on target genes leading to enhanced histone acetylation,
chromatin remodelling, and gene activation [8–14].
The discovery that PADI4 is a nuclear enzyme which converts
histone arginine residues to citrulline [15] provided the first
evidence that PADI4 may play a role in gene regulation. This
prediction was validated by the findings that PADI4 mediated
citrullination of histone arginine residues (both unmodified and
monomethylated) at the hormone dependent TFF1 promoter [16–
18], and at the apoptosis related gene promoters, p21 and OKL38
[19,20], represses gene transcription. However, due to the limited
number of target genes identified to date, our understanding of the
gene regulatory potential of PADI4 remains far from complete.
Therefore, to more fully elucidate the repertoire of PADI4 target
genes, in this study we first carried out ChIP-chip analysis using a
PADI4-specific antibody in MCF-7 cells. Surprisingly, in addition
to the previously described repressive role for PADI4 in
transcription, we found that PADI4 is also associated with a large
set of actively transcribed genes and appears to function as a
transcriptional coactivator of at least a subset of these genes.
Computational analysis then found that our PADI4 ChIP-chip
data set is strongly correlated with published data sets from
activating, but not repressive, markers and that several common
transcription factor binding sites are enriched around PADI4
peaks, with the V$ELK1_02 motif being the most significant
element. We then demonstrate that PADI4 interacts with Elk-1
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and that citrullination of Elk-1 by enzymatically active PADI4
facilitates ERK-mediated phosphorylation of Elk-1 in vitro.
Further, we show that either suppression of PADI4 or inhibition
of PADI4 activity leads to reduced Elk-1 phosphorylation and
histone H4 acetylation on the c-Fos promoter. These mechanistic
studies support the hypothesis that PADI4 enzymatic activity
potentiates two key features of c-Fos transcriptional activation; Elk-
1 phosphorylation and histone acetylation.
Results
PADI4 Is Enriched near Gene Promoter Transcription Start
Sites (TSSs)
The PADI4 antibody utilized for this study was selected because
the immunogenic peptide sequence (N-terminal amino acids 1–15)
is unique to PADI4 among the PADI family members (Figure
S1A). In our study, an overexpressed Flag-tagged version of
PADI4 was readily detected in MCF-7 cell extracts by western blot
using both the anti-PADI4 antibody and an anti-Flag antibody,
indicating accuracy of PADI4 antibody targeting. Furthermore,
this antibody recognized PADI4 in the lysates of MCF-7 cells that
had been transfected with PADI4 expression vector, but not in
cells transfected with any other PADI family members, confirming
antibody specificity (Figure S1B and S1C). Additionally as shown
in Figure S2, ChIP analysis found that the PADI4 antibody also
bound to the previously reported PADI4 targets, OKL38 and p21.
To identify PADI4 targets in an unbiased genome-wide manner,
we performed ChIP in MCF-7 cells using the PADI4-specific
antibody and then hybridized the enriched genomic DNA to
promoter tiling arrays which spanned 2.7 kb of the gene promoter
regions (2.2 kb upstream and 500 bp downstream relative to the
TSS). The array represented 51 Mbp of genomic DNA, including
nearly all known well-characterized RefSeq genes (19206 promoters
total). The raw ChIP-chip signal to input ratios were processed as
described in Materials and Methods. Significant PADI4 peaks were
defined as the center of three consecutive windows with positive
means (using at least six probes) and the center window having a
mean greater than either adjacent window. The P-values for all the
peaks were calculated using the nonparametric Wilcoxon signed-
rank test. A total of 1124 peaks of PADI4 genomic binding were
identified using a threshold P-value of less than 0.016 (Table S1).
The use of this selection criterion was validated by conventional
ChIP-qPCR analyses on the randomly selected peaks from the array
(Figure S3) which showed a false positive rate (FPR) of less than
15%. As demonstrated by the strong correlation between the
window averages from the ChIP-chip replicates (Figure 1A), the
ChIP-chip results were found to be highly reproducible. To match
the identified peaks with all well-characterized RefSeq genes, we
examined the distribution of PADI4 peaks throughout the whole
promoter region and aligned the peaks to the TSSs for all the genes
within the array. Surprisingly, our heat map analysis showed an
apparent enrichment of PADI4 in the region surrounding the TSS
(Figure 1B). We next determined distribution of the distances of
each significant PADI4 peak to the closest TSS and observed that
the PADI4 peaks are statistically enriched around the TSSs
(Figure 1C), suggesting that PADI4 may be involved in transcription
factor mediated gene expression.
PADI4 Levels Surrounding TSSs Are Positively Correlated
with Gene Expression
To explore the relationship between PADI4 and gene
expression in more detail, we compared our PADI4 ChIP-chip
data sets with gene expression microarray analyses from MCF-7
cells that had been grown under similar conditions (Affymetrix
expression arrays, U133A, GEO accession number GSE9253).
We first plotted the average signal intensities for PADI4 around
the TSSs for all of the genes in the expression microarray
following sorting of these genes into ten distinct expression level
subsets by decile (1st being lowest 10% and 10th being highest
10%). As shown in Figure 2A, most genes with either low or no
expression (1st decile) are not bound by PADI4. The average
PADI4 ChIP-chip signal is then seen to increase around the TSS
concordant with increasing levels of gene expression, with the
10th decile showing the highest level of PADI4 binding. We then
grouped all of the expressed genes (5696) in the microarray and
identified 516 genes (9.1%) as having significant PADI4 peaks
(p,0.016, Wilcoxon signed-rank test) while only 77 (1.8%) of the
4333 unexpressed genes showed significant PADI4 peaks, thus
indicating a 5.1-fold enrichment of PADI4 at expressed genes
(Fisher’s Exact Test, p,1610250) compared to unexpressed
genes (Figure 2B). This result supports a positive role of PADI4 in
gene transcription. To gain further insight into the biological
importance of the PADI4-bound genes, we determined the
ontological gene categories by gene function analysis using
DAVID (See Functional classification and annotation of the
candidate genes, Genomic data analyses). As shown in Table 1
and Table S2, these genes encode proteins that are involved in a
range of processes, with some of the most significant enrichment
scores being for genes associated with membrane and organelle
lumens, the nuclear lumen, protein catabolism, RNA processing,
nucleotide binding, chromatin function, and ribosomal biogen-
esis. Next, we tested for a functional link between PADI4 and
gene expression by evaluating the expression of a subset of
PADI4-bound genes in both control MCF-7 cells and in stable
short hairpin RNA (shRNA)-mediated PADI4 knockdown MCF-
7 cells (Figure 2C and 2D). For each gene, we tested both gene
expression by reverse transcription (RT)-qPCR and PADI4
promoter binding by ChIP-qPCR. Genes with reduced expres-
sion in the PADI4 knockdown also showed decreased PADI4
promoter binding while the expression of the GAPDH house-
keeping gene (which is not bound by PADI4 at its promoter)
remained unchanged in the PADI4 knockdown. This analysis
Author Summary
Peptidylarginine deiminase 4 (PADI4) converts positively
charged arginine and methylarginine residues on histones
to the neutrally charged non-standard amino acid
citrulline. We and others have previously shown that
citrullination of a small subset of gene promoters, such as
the estrogen receptor target, TFF1, appears to downreg-
ulate gene expression. In this study, we looked across the
human genome using ChIP-chip to better define the full
repertoire of genes that are regulated by PADI4 in breast
cancer cells. Surprisingly, we found that PADI4 appears to
primarily be involved in gene activation, as opposed to
gene repression. Further, we found that PADI4 is likely
recruited as a co-activator to these target genes by a range
of well-defined transcription factors, such as Elk-1. With
respect to how PADI4 activates gene transcription, we
show that PADI4 directly interacts with Elk-1 at its well-
defined target, the c-Fos oncogene. Additionally, we found
that, following stimulation with epidermal growth factor,
PADI4 appears to directly target Elk-1 for citrullination,
which in turn leads to increased histone acetylation and
gene transcription. These novel genome-wide and gene-
specific findings suggest that PADI4 plays a much broader
role in gene activation than previously thought.
PADI4 and Gene Regulation
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further confirms the hypothesis that PADI4 binding is well
correlated with transcriptional activation.
To further test the hypothesis that PADI4 promoter binding
correlates with transcriptional activation, we next compared our
PADI4 ChIP-chip dataset with multiple published ChIP-chip
datasets for factors that are well correlated with gene regulation
(http://www.ncbi.nlm.nih.gov/geo) [21]. The spearman correla-
tion was determined between windows of the PADI4 ChIP-chip
and identical windows within each of ChIP-chip data sets
incorporated in the database. Volcano plots showed both sta-
tistically significant positive (Figure 2E, on the right) and neg-
ative (Figure 2E, on the left) correlations between the published
ChIP-chip datasets and our PADI4 dataset. For example, as
shown in Figure 2F, the PADI4 ChIP-chip output is significantly
correlated with output from factors associated with gene activation
such as the transcription factors E2F1 and RNAPII [22–25], the
chromatin modulating protein PARP-1 [26] and the histone
varaiant H2A.Z [27]. On the other hand, the PADI4 ChIP-chip
dataset is negatively correlated with datasets from factors
associated with gene repression such as the H3me3K9 and
H3me3K27 histone modifications and methylated DNA (5-meC)
[13,28,29]. Taken together, this computational analysis again
suggests that PADI4 binding plays a role in the activation of a
subset of actively transcribed genes.
Combinatorial Promoter Targeting by PADI4 and Active
Elk-1
To identify specific transcription factors that might utilize
PADI4 to mediate transcriptional output, we computationally
explored the promoter regions of genes with significant PADI4
binding (p,0.016) to identify putative DNA binding motifs within
the bound regions (See Enrichment of Transcription Factor
Binding Sites [TFBS] Analysis, Genomic data analyses). The
analysis identified a number of highly enriched DNA binding
elements for transcription factors such as STAT1/3, NFY, and
E2F, suggesting the possible involvement of these cis-elements in
the underlying regulatory control of PADI4 at target genes
(Figure 3A and Figure S4). The transcription factor binding site
showing the highest level of significance (Fisher exact test,
p = 5.56E-235) was V$ELK1_02, which contains the consensus
motif CCGGAA. This motif was originally identified as a binding
site for the oncogene, Elk-1, and has since been found to be bound
by other ETS family members such as Ets1 and GABPa [30–32].
Interestingly, of the 516 gene promoters showing significant
PADI4 binding, 70 genes (13.56%) were found to also contain the
V$ELK1_02 site adjacent to, or overlapping PADI4 peaks.
Further, a ChIP-chip data set is publically available for Elk-1
[33] and a comparison of our PADI4 dataset with this data showed
that 15.7% of PADI4 peaks are found within 1.5 kb of Elk-1 peaks
Figure 1. PADI4 is enriched in the gene promoter region near the TSSs. (A) Scatterplot showing the mean log2 ratio of each window on the
array for two PADI4 ChIP-chip replicates. The spearman rank correlation coefficient and associated p-value are indicated. (B) Heat map of PADI4 ChIP-
chip data for 19,206 promoters from22,200 bp to +500 bp relative to the TSS. The values in the x-axis represent the center of a 600 bp window with
150 bp steps relative to each TSS. The promoters are ordered top to bottom based on the increasing intensity of the PADI4 signal at the promoter
surrounding the TSSs. (C) Histogram showing the number of statistically significant peaks (Wilcoxon signed-rank test, p,0.016) across the entire tiled
region for all the promoters on the ChIP-chip array. The asterisk denotes significant enrichment of PADI4 peaks near the TSSs based on the p-value
from a Fisher exact test (*p = 0.0444, **p = 0.0085, ***p = 6.2161029, ****p = 1.42610215).
doi:10.1371/journal.pgen.1002112.g001
PADI4 and Gene Regulation
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Figure 2. PADI4 recruitment at gene promoters correlates with the actively transcribed genes. (A) The average log2 enrichment ratio
from PADI4 ChIP-chip is displayed for the genes in the MCF-7 cell cDNA microarray by decile of expression level from lowest (1st) to highest (10th). (B)
Percentage and fold enrichment of PADI4-bound expressed and unexpressed genes. (C) Western Blot showing the shRNA-mediated depletion of
PADI4 in MCF-7 cells versus shRNA control knockdown cells. (D) Gene-specific analysis of mRNA expression by RT-qPCR and PADI4 promoter binding
by ChIP-qPCR in shRNA control and PADI4 knockdown MCF-7 cells. Expression data are normalized to b-actin transcripts and the graph is mean +
SEM. The non-specific binding in the ChIP assay is indicated by the horizontal dotted line. (E) Volcano plot of computational comparison of PADI4
ChIP-chip dataset with multiple published ChIP-chip datasets. The score of each correlation was defined as the negative of the log10 of the p-value for
the correlation. (F) PADI4 ChIP-chip is positively correlated with the ChIP-chips assayed by gene activating markers (in red) while negatively correlated
with the ChIP-chips assayed by gene silencing markers (in black). The data shown here represent a subset of the data shown in Figure 2E.
doi:10.1371/journal.pgen.1002112.g002
PADI4 and Gene Regulation
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(Table 2), suggesting that Elk-1 is significantly enriched near
PADI4 peaks. This observation suggested that Elk-1 may utilize
PADI4 as a cofactor to help mediate transcriptional activation.
To begin testing this hypothesis experimentally, we performed
independent PADI4 and Elk-1 ChIP experiments using identical
promoter primers to test whether Elk-1 and PADI4 bound to the
promoters of a subset of genes identified as having PADI4 peaks
and the V$ELK1_02 element. Results show that, as predicted,
both PADI4 and Elk-1 bound to the same promoter regions of this
subset and not to the promoters of a subset of control genes
identified as both PADI4 and V$ELK1_02 negative (Figure 3B).
To test if PADI4 and Elk-1 might coregulate the expression of this
bound subset, we generated a stable Elk-1 knockdown MCF-7 cell
line (Figure 3B, bottom panel, inset) and then evaluated the
expression of the bound and unbound genes in the Elk-1 and
PADI4 knockdown lines. We found that PADI4 or Elk-1 depletion
in MCF-7 cells reduced the expression of the bound genes while
expression of unbound genes (shaded in gray) remained
unchanged (Figure 3B). These results support the hypothesis that
Elk-1 may utilize PADI4 as a co-factor to regulate gene expression.
To further test this hypothesis, we next carried out co-
immunoprecipitation analysis to establish whether Elk-1 and
PADI4 interact. We first confirmed the specificity of the anti-Elk-1
antibody in HEK293 cells by depleting Elk-1 and showing that
levels of the anti-Elk-1-reactive band were greatly reduced (Figure
S5). Next, we transiently transfected Flag-tagged PADI4 into 293
cells and immunoprecipitated with anti-Flag antibody followed by
western blot analysis using antibodies against both Elk-1 and
phospho-Elk-1 (p-Elk-1). As shown in Figure 3C, a substantial
amount of Elk-1 and p-Elk-1 was co-precipitated from cells
expressing Flag-PADI4, but not from cells lacking Flag-PADI4.
Additionally, we also found that levels of p-Elk-1 binding to
PADI4 increased following stimulation with EGF (Figure 3C).
Reciprocally, we also found that the endogenous Elk-1 proteins
were immunoprecipitated with anti-Elk-1 antibody, and the co-
precipitated PADI4 proteins were subsequently detected using the
anti-PADI4 antibody, while PADI4 was not coimmunoprecipi-
tated with the normal rabbit IgG control (Figure 3C). These results
indicated that both Elk-1 and the active form of Elk-1 can
physically associate with PADI4. The interaction of PADI4 and
phosphorylated Elk-1 supports the hypothesis that PADI4 may
play a direct role in facilitating Elk-1 target gene activation.
Perhaps the best-characterized Elk-1 target is the immediate
early oncogene c-Fos. The SRE cis element that mediates c-Fos
transcriptional activation contains the Elk-1 binding element and
is recognized by the Elk-1-containing ternary complex factor [34].
This observation prompted us to examine whether the location of
PADI4 on the c-Fos promoter (as determined by ChIP-chip) is near
the SRE region. Interestingly, PADI4 binding was found to
primarily occur in the proximal promoter region of c-Fos, covering
the SRE motif (Figure 3D and 3E). This result implied that PADI4
and Elk-1 may also target the same promoter region of c-Fos.
Therefore, we further characterized this interaction on the tiled
regions of the c-Fos promoter by performing PADI4, Elk-1 and
p-Elk-1 ChIPs in MCF-7 cells (Figure 3E). In line with our
hypothesis, we found endogenous PADI4 to be enriched spe-
cifically around the SRE motif on the c-Fos promoter but not
on promoter regions more removed from the TSS (,500 bp
upstream of the SRE or downstream of the TSS). We also
observed a near perfect overlap between PADI4, p-Elk-1, and Elk-
1 at the c-Fos promoter by ChIP q-PCR. Given these observations,
and that PADI4 interacts with Elk-1 in 293 cells, we also carried
out ChIP-re-ChIP analysis using anti-PADI4 antibody for the first
round of IP and then anti-Elk-1 for the second round of IP. Results
showed that endogenous PADI4 appears to physically associate
with Elk-1 at the c-Fos SRE region (Figure 3E, bottom). Given
these observations, we next decided to more closely investigate the
role of PADI4 in c-Fos regulation to gain mechanistic insight into
PADI4’s role in transcriptional activation.
PADI4 Mediates Expression of the Elk-1 Target Gene c-Fos
EGF can activate c-Fos expression in MCF-7 cells [35] and this
response is accompanied by activation of Elk-1 via MAPK/ERK
phosphorylation, by which the SRE cis element that mediates c-Fos
transcriptional activation is recognized [8,10,11]. Given our
finding that PADI4 and active Elk-1 strongly co-occupy the c-Fos
promoter, we hypothesized that c-Fos expression may be regulated,
in part, by the interplay between PADI4 and Elk-1. To address
this question, we first tested the effects of inhibition of either Elk-1
or PADI4 activity on c-Fos expression following EGF stimulation.
We inhibited PADI4 enzymatic activity using a newly developed
arginine-based PADI inhibitor, Cl-Amidine [36], which has been
shown to inhibit PADI4 activity at gene promoters in several
cancer cell lines [19,20]. As shown in Figure 4A, stimulation of
MCF-7 cells with EGF (50 ng/ml) for 30 min elicited a dramatic
increase of c-Fos mRNA expression. As expected, pretreatment of
MCF-7 cells with the ERK inhibitor U0126 abrogated c-Fos
activation following EGF stimulation. Interestingly, Cl-Amidine
also strongly inhibited c-Fos activation by EGF (Figure 4A) and this
inhibition was found to be dose-dependent (Figure S6). We also
observed by western blotting that Cl-Amidine globally suppresses
Elk-1 phosphorylation in a dose-dependent manner, while having
Table 1. Gene ontology analysis for the transactive genes
associated with PADI4 binding in MCF-7 cells.
Gene ontology term Aspect P-value
membrane-enclosed lumen CC 1.66E-12
intracellular organelle lumen CC 3.43E-11
organelle lumen CC 5.00E-11
nuclear lumen CC 1.69E-09
ribonucleoprotein complex CC 7.50E-09
non-membrane-bounded organelle CC 1.35E-07
intracellular non-membrane-bounded organelle CC 1.35E-07
macromolecule catabolic process BP 3.11E-11
cellular macromolecule catabolic process BP 4.88E-11
modification-dependent macromolecule catabolic process BP 1.19E-09
modification-dependent protein catabolic process BP 1.19E-09
proteolysis involved in cellular protein catabolic process BP 1.57E-09
protein catabolic process BP 1.62E-09
cellular protein catabolic process BP 1.83E-09
nucleotide binding MF 1.37E-07
ATPase activity MF 6.05E-06
purine nucleotide binding MF 2.22E-05
ribonucleotide binding MF 2.62E-05
purine ribonucleotide binding MF 2.62E-05
RNA binding MF 3.89E-05
nucleoside binding MF 1.14E-04
The analysis was performed for all three gene ontology aspects: cellular
component (CC), biological process (BP) and molecular function (MF). The seven
most significant gene ontology terms for each aspect are listed. For a more
complete list of significantly enriched ontologies, refer to Table S2.
doi:10.1371/journal.pgen.1002112.t001
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Figure 3. Co-occupancy by PADI4 and Elk-1 on a subset of Elk-1 target gene promoters. (A) Identification of enriched TFBS within the
promoter regions of the significant PADI4 bound genes (p,0.016). The bar chart displays the negative log of the enrichment P values using Fisher
exact test for the top 21 motifs. The most significant V$ELK1_02 is shown on the right in black. (B) Gene-specific analysis of promoter binding by
PADI4 and Gene Regulation
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little effect on ERK phosphorylation (Figure 4B). These observa-
tions suggests that the effect of Cl-Amidine on c-Fos transcription
occurs downstream of ERK kinase, likely at the level of Elk-1
phosphorylation. Note: Given the strong suppressive effect of
U0126 in c-Fos expression, we were not able to quantitatively test
for possible synergy between this drug and Cl-Amidine. To control
for non-specific effects of the drugs on transcription, levels of
GAPDH housekeeping gene were also monitored and neither
inhibitor altered the expression of this gene. As another test of the
collaborative role of PADI4 and Elk-1 in c-Fos activation, we
investigated c-Fos expression following EGF stimulation in the Elk-
1 and PADI4 knockdown lines. As predicted, depletion of either
PADI4 or Elk-1 reduced c-Fos expression upon EGF stimulation
(Figure 4C and 4D). We then generated a stable PADI4-
overexpressing line and found c-Fos expression to be elevated in
this line in both un-stimulated and EGF stimulated conditions
(Figure 4E). We also tested whether the observed inhibitory effect
of Cl-Amidine on c-Fos transcription is preserved in other breast
cancer cell lines by treating BT474 (ER+, HER2+) and MCF10A-
DCIS (ER2, HER2+) cells with the inhibitor. Results showed that
Cl-Amidine treatment inhibits EGF-induced c-Fos expression in
both of these lines, with the strongest inhibitory effect being
observed in the BT474 line (Figure S7).
We next investigated whether PADI4 and Elk-1 might
coregulate gene activation on a more generalized template in vitro.
For this experiment, we fused full length Elk-1 to the GAL4 DNA-
binding domain, and transfected this construct alone or with either
WT PADI4 or the PADI4 catalytic mutant (CS) into 293 cells. We
then tested the effects of these constructs on GAL4-driven
luciferase reporter activity. Results showed that while GAL4-Elk-
1 did not activate transcription over GAL4 alone, cotransfection of
WT PADI4 with Elk-1 resulted in enhanced luciferase activity
(Figure 4F). PADI4 enzymatic activity appears to be required for
reporter activity because cotransfection of GAL4-Elk-1 with
inactive PADI4 did not increase reporter activity above that of
Elk-1 alone. We also carried out luciferase reporter experiments
using a c-Fos-luciferase reporter system and obtained similar results
(Figure S8). Collectively, the above data support the hypothesis
that a functional relationship between Elk-1 and PADI4 on gene
promoters potentiates Elk-1 mediated gene transcription. To
further test this hypothesis and to investigate whether Elk-1
recruits PADI4 to its target promoters (or possibly vice versa), we
then carried out ChIP-qPCR analysis with PADI4 and Elk-1
antibodies in serum-starved MCF-7 cells, in cells treated with
EGF, and in EGF-stimulated cells that had been pretreated with
inhibitors. Results showed that binding of PADI4 and Elk-1 at the
c-Fos SRE promoter region was independent of EGF, U0126 or
Cl-Amidine treatment (Figure 5A). Additionally, we found that
PADI4 occupancy was decreased at the c-Fos SRE region upon
PADI4 knockdown, while depletion of PADI4 did not change Elk-
1 occupancy at c-Fos (Figure 5B). On the other hand, depletion of
Elk-1 not only caused a decrease in Elk-1 at the c-Fos promoter but
also reduced PADI4 enrichment at this site (Figure 5C). The
binding of Elk-1 at c-Fos promoter before and after EGF
stimulation is consistent with previous reports showing that Elk-1
constitutively binds to c-Fos promoter [9,37]. Given that PADI4
has no distinguishable DNA binding motif and that PADI4 has
been found to be targeted to specific gene promoters by
transcription factors such as p53 [19], our results suggest that
PADI4 recruitment to the c-Fos promoter is Elk-1-dependent.
In order to further test how PADI4 regulates c-Fos activity, we
next tested the effects of PADI4 inhibition or depletion on Elk-1
phosphorylation and on histone H4K5 acetylation (Ac-H4K5) at
the c-Fos SRE following EGF stimulation in MCF-7 cells (Figure 5).
Results showed that EGF treatment resulted in a strong
enrichment of p-Elk-1 and Ac-H4K5 at the c-Fos promoter
(Figure 5A) and that this enrichment was abrogated by
pretreatment with the PADI4 inhibitor (Figure 5A) or by PADI4
depletion (Figure 5B). Additionally, as expected, both ERK
inhibition (U0126, Figure 5A) and Elk-1 depletion (Figure 5C)
also reduced p-Elk-1 and Ac-H4K5 enrichment at c-Fos promoter
following EGF stimulation.
Citrullination of Elk-1 by PADI4 Potentiates Elk-1
Phosphorylation
The findings that PADI4 interacts with Elk-1 on c-Fos and that
PADI4 inhibition suppressed phosphorylation of Elk-1 (but not
ERK) suggested that PADI4 may regulate c-Fos activation by
Table 2. Comparison of PADI4 ChIP-chip with Elk-1 ChIP-chip dataset [33].
Test factor Co-occupied peaks Only test Only PADI4 Fold enrichment p-value % of test % of PADI4 Cell line
Elk-1 119 367 638 55.4 3.36E-147 24.5 15.7 Serum-starved Hela Cells
doi:10.1371/journal.pgen.1002112.t002
PADI4 and Elk-1 using ChIP-qPCR in MCF-7 cells (upper panel) and mRNA expression by RT-qPCR in shRNA control and PADI4 knockdown (middle
panel) or Elk-1 knockdown MCF-7 cells (lower panel). The insert in the lower panel shows the shRNA-mediated depletion of Elk-1 in MCF-7 cells versus
shRNA control cells by western blot. For each gene, the independent PADI4 and Elk-1 ChIP experiments were performed with the same promoter
primers. The non-specific binding in the ChIP assay is indicated by the horizontal dotted line. Expression data are normalized to GAPDH transcripts and
the graph is mean + SEM. The control genes without potential binding sites for both PADI4 and Elk-1 on the promoter are shown in the gray shadow.
(C) Co-IP assays in 293 cells reveal that PADI4 interacts with both Elk-1 and phospho-Elk-1. Lysates of HEK293 cells transfected with a plasmid carrying
Flag-PADI4 were immunoprecipitated with anti-FlagM2 affinity gel followed by western blot analysis using antibodies against Elk-1, phospho-Elk-1 and
PADI4 (upper andmiddle left). Endogenous Elk-1 proteins were immunoprecipitated with anti-Elk-1 antibody, and co-precipitated PADI4 proteins were
subsequently detected with anti-PADI4 antibody (bottom left). Immunoblot on the bottom right shows increased levels of p-Elk-1 binding to PADI4
following stimulation with EGF. HEK293 cells were transiently transfected with PADI4, serum starved, and stimulated with EGF. Immunoprecipitations
of cell lysates was then performed using the anti-PADI4 antibody and immunoblots were then probed with both anti-p-Elk-1 and anti-Elk-1. Normal IgG
antibody was used as a control. (D) PADI4 ChIP-chip signal localizes to the proximal c-Fos promoter. (E) ChIP-qPCR showing that PADI4 and activated
Elk-1 specifically bind at the c-Fos SRE promoter region in MCF-7 cells. The schematic at the top of the figure indicates the locations of the primer sets
used for ChIP assays relative to the TSS. The SRE region is marked. The non-specific binding in the ChIP assay is indicated by the horizontal dotted line.
Data are represented as mean + SEM (n= 3). ChIP-re-ChIP experiments (bottom) detected simultaneous binding of PADI4 and Elk-1 to the c-Fos SRE
region in MCF-7 cells. The first step ChIP was performed using anti-PAD4 antibody and the second step ChIP was performed using anti-Elk-1 antibody.
IgG was used as an irrelevant control.
doi:10.1371/journal.pgen.1002112.g003
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Figure 4. PADI4 mediates expression of the Elk-1 target gene c-Fos. (A, C and D) Real-time RT-PCR analysis of the c-Fos and GAPDH
expression in serum-starved or EGF-stimulated MCF-7 cells (A) with or without Cl-Amidine or U0126 treatment; (C) with or without PADI4 knockdown;
(D) with or without Elk-1 knockdown. Expression data are normalized to b-actin transcripts and the graph represents the mean + SEM (n= 3). *P,0.05,
**P,0.01. (B) Dose-dependent effect of Cl-Amidine treatment on Elk-1 activation and ERK2 phosphorylation in MCF-7 cells. Different doses of Cl-
Amidine were added to the normal MCF-7 cell culture media for 48 hours and western blots of cell lysates were then performed using anti-p-Elk-1,
anti-Elk-1, anti-p-ERK and ERK2 antibodies. The graph on the right is a semi-quantitative analysis of the western blots (relative intensity) with an
arbitrary number of the intensity ratio of p-Elk-1 compared to total Elk-1, or p-ERK compared to total ERK2 using Image J software. (E) Stable
overexpression (OE) of PADI4 in MCF-7 cells increases transcriptional output of c-Fos. Left: qRT-PCR analysis showing that PADI4 expression is
increased in PADI4 OE MCF-7 cells. Right: qRT-PCR analysis showing that c-Fos transcription output was significantly elevated in PADI4 OE MCF-7 cells
under either control or EGF treatment. (F) PADI4 enzymatic activity facilitates Elk-1 mediated gene transcription. Expression vector for the DNA-
binding domain of GAL4 (CMV-GAL4) or GAL4-Elk-1 was transfected into HEK293 cells along with the 5xGAL4-driven luciferase reporter plasmid
containing the minimal E1b promoter and plasmids for pcDNA3.1, wild type (WT) or inactive mutant (C645S) PADI4 with N-terminal Flag tags.
Luciferase activity was determined per microgram total cell protein 24 hours after transfection and results are represented as fold relative to empty
vector control. Data shown are representative of two independent experiments performed in triplicate and error bars indicate SEM. *P,0.05 (two-
tailed paired Student’s t-test). In the lower panel, the expression of Flag-PADI4 and GAL4-Elk-1 fusion proteins was monitored by western blot using
anti-Flag and anti-GAL4 antibodies.
doi:10.1371/journal.pgen.1002112.g004
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directly targeting Elk-1 for citrullination. To test the hypothesis,
we first investigated whether PADI4 can citrullinate Elk-1 in vitro.
Endogenous Elk-1 was immunoprecipitated from MCF-7 cells,
treated with recombinant PADI4 (WT or CS), and the resolved
proteins were then probed with an antibody that is reactive with
citrullinated proteins (anti-pan-cit, [38]). Results (Figure 6A) show
that the anti-pan-cit antibody was reactive with an appropriately
sized band from the anti-Elk-1 immunoprecipitate (lane 4) and was
not reactive with proteins from the anti-Elk-1 immunoprecipitate
(lane 3) that had been treated with the PADI4 C645S mutant or
from proteins immunoprecipitated with IgG (lanes 1 and 2). Anti-
Elk-1 and anti-PADI4 western blots confirmed equal protein
loading. These results support the hypothesis that Elk-1 is a target
for PADI4 mediated citrullination.
Transcriptional activation of c-Fos is initiated following phos-
phorylation of Elk-1 by ERK kinase. The above findings raised the
possibility that citrullination of Elk-1 by PADI4 may facilitate ERK-
mediated phosphorylation of Elk-1. To test this hypothesis, we then
performed ERK kinase assays on in vitro translated WT or inactive
mutant (DN) Elk-1 following pretreatment with either WT or
catalytically inactive (CS) PADI4. As shown in Figure 6B, in the
presence of activated ERK2, higher levels of Elk-1 Ser383
phosphorylation were observed following pretreatment of Elk-1
with WT PADI4 (lane 5) when compared to pretreatment with
inactive PADI4 (lane 6). A similar decrease in Elk-1 Ser383
phosphorylation levels was observed with the ERK2 isolated from
the non-EGF stimulated JEG3 cells following treatment of Elk-1
with mutant PADI4, though the overall signal intensities were much
lower (lanes, 1 and 2). As expected, phosphorylation of DN Elk-1
was below the limit of detection (lanes 3, 4, 7 and 8), thus confirming
anti-p-Elk-1 antibody specificity. Total Elk-1 levels were also
evaluated with anti-Elk-1 antibody to normalize for protein loading.
Figure 5. PADI4 enzymatic activity facilitates c-Fos transcription via regulation of Elk-1 phosphorylation and/or HAT-mediated
histone acetylation. (A–C) ChIP-qPCR analysis of PADI4, Elk-1, p-Elk-1, and Ac-H4K5 binding at c-Fos promoter in serum-starved or EGF-stimulated
MCF-7 cells; (A) in the absence or presence of Cl-Amidine or/and U0126 treatment; (B) with or without PADI4 knockdown; or (C) with or without Elk-1
knockdown. The IgG control in the ChIP assay is indicated by the horizontal dotted line.
doi:10.1371/journal.pgen.1002112.g005
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Additionally, the blots were also probed with anti-phosphorylated
ERK antibody to confirm that EGF treatment of JEG3 cells
activated ERK2 and with anti-ERK2 antibody to further confirm
equal protein loading. Collectively, these results support the
hypothesis that PADI4 mediated citrullination facilitates phosphor-
ylation of Elk-1 by ERK.
Discussion
Given previous findings indicating that PADI4 plays a
repressive role in gene transcription, we were initially surprised
by our global analysis showing that PADI4 binding is primarily
correlated with active gene transcription. However, the prediction
that PADI4 also appears to play an important role in the
activation of a broad range of target genes is supported by the
following new lines of evidence. Firstly, we found that the PADI4
binding pattern near the TSSs is highly correlated with actively
transcribed genes in MCF-7 cells and that most genes not
expressed in the array are not bound by PADI4. Secondly, our
computational ChIP-chip dataset analysis found that PADI4 is
highly positively correlated with datasets from factors associated
with gene activation and negatively correlated with datasets from
factors associated with gene repression. Lastly, our computational
analysis of transcription factor binding sites found that PADI4 is
significantly enriched on promoters which contain DNA binding
elements for a broad range of activating transcription factors.
Interestingly, several of the elements identified in our computa-
tional analysis are bound by transcription factors such as STAT1,
STAT3, STAT5, ETS1, PAX and E2F, which play important
roles in mammary function and in breast cancer [39–44]. Thus,
the finding that PADI4 binding is enriched near these elements in
MCF-7 cells supports the hypothesis that PADI4 plays a role in
regulating target gene expression in a range of mammary gland
signaling pathways.
Given that PADI4 binding was frequently coincident with the
Elk-1 DNA binding element, and that PADI4 interacts with Elk-1,
we next focused on investigating the potential relationship between
PADI4 and Elk-1 on the c-Fos promoter, in order to better
understand how PADI4 may activate gene transcription. Our
findings that endogenous c-Fos levels were suppressed in PADI4
depleted and inhibitor-treated lines and elevated in PADI4
overexpressing cells, supported our genome-wide finding that
PADI4 plays a role in transcriptional activation. Next, the
observations that PADI4 interacts with Elk-1 at c-Fos and that
PADI4 facilitates Elk-1-mediated activation of both a ubiquitous,
and c-Fos-specific, reporter systems suggested that a functional
relationship between Elk-1 and PADI4 confers activation of c-Fos.
As to potential mechanisms behind this functional relationship, we
found that PADI4 can citrullinate Elk-1 in vitro and that PADI4
enzymatic activity facilitates Elk-1 phosphorylation on c-Fos. Our
ERK kinase assay then demonstrated that citrullination of Elk-1
by PADI4 enhances ERK-mediated Elk-1 phosphorylation.
Finally, the observation that histone H4K5 acetylation was
suppressed at c-Fos following PADI4 inhibition or depletion
suggested that the observed PADI4 enzymatic activity on Elk-1
phosphorylation at c-Fos then facilitated histone acetylation and
subsequent c-Fos activation.
The potential role for PADI4 in c-Fos activation is partially
clarified when the above findings are put in the context of what is
currently known about the role of Elk-1 in this process. Recent
reports have demonstrated that unphosphorylated Elk-1 and p300
form complexes and bind to gene promoters in the absence of
stimuli. Following stimulation, Elk-1 is then phosphorylated by
ERKs and this phosphorylation event strengthens the interaction
Figure 6. Citrulliantion of Elk-1 by PADI4 potentiates Elk-1
phosphorylation. (A) Citrullination of Elk-1 by enzymatically active PADI4
In vitro. Elk-1 protein fromMCF-7 cells was immunoprecipitated by anti-Elk-1
antibody and then treated with either WT or C645S mutant PADI4 purified
from the Ni-NTA column. The reactions were assessed by western blot
analysis with an antibody that recognizes citrullinated proteins (anti-pan-
citrulline antibody). IgG was used as internal control. (B) In vitro citrullination
of Elk-1 by active PADI4 facilitates the activation of Elk-1 by ERK2 kinase.
JEG3 cells were serum starved and then treated with 50 ng/ml EGF for
30 min. The cells were lysed and ERK2-containing proteins were
immunoprecipitated with anti-ERK2 antibody. His-tagged PADI4 (WT or
C645S catalytic inactive mutant) purified from the Ni-NTA column was used
to treat the in vitro translated Elk-1 (WT or DN mutant). The PADI4-treated
Elk-1 was then incubated with immobilized ERK2 for the kinase assay. The
products were detected by Western blotting with antibodies to p-Elk-1, Elk-
1, p-ERK, and ERK2. The graph below indicates densitometric analysis of
western blots (relative intensity) with an arbitrary number of the intensity
ratio of p-Elk-1 to total Elk-1 using Image J Software.
doi:10.1371/journal.pgen.1002112.g006
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between Elk-1 and p300, leading to enhanced histone acetyltrans-
ferase activity at target promoters and gene activation [9,14]. In
addition to observed Elk-1/p300 interactions, p300 has also been
found to be targeted by PADI4 for citrullination [45]. Given these
observations, and our findings that PADI4 interacts with Elk-1 and
that Elk-1 depletion reduces PADI4 levels at c-Fos, it seems likely
that Elk-1, p300, and PADI4 are constitutively bound to the c-Fos
promoter (Figure 7). Our current working model then predicts that
treatment of MCF-7 cells with EGF then activates PADI4, which,
in turn, citrullinates Elk-1. Upon citrullination, Elk-1 is then
phosphorylated by ERK2 leading to stronger associations between
Elk-1 and p300, increased histone acetylation, and subsequent
transcriptional activation [4,8,10,46]. Given that citrullination
neutralizes positively charged arginine residues, it seems possible
that PADI4-mediated citrullination facilitates ERK-mediated
phosphorylation of Elk-1 by allowing this kinase closer access to
its target serine residues. As an alternate hypothesis to our working
model, Lee et al. [45] has found that PADI4 can also directly
citrullinate p300 to enhance p300 activity. Thus, it is possible that
a direct functional relationship exist between PADI4 and p300 on
c-Fos. However, we found that treatment of p300 with PADI4 did
not enhance p300’s histone acetyltransferase activity in vitro (data
not shown). Additionally, we do not believe that PADI4 is
mediating c-Fos activity via histone citrullination as we were not
able to detect significant increases of citrullinated histones (H3 or
H4) on the c-Fos promoter after EGF stimulation (data not shown).
Given these observations, and our findings presented here, the
most likely mechanism by which PADI4 is regulating c-Fos is by
targeting Elk-1 for citrullination.
In conclusion, our genomic analysis has identified a new role for
PADI4 in mediating gene transactivation. We present evidence
that a broad range of transcription factors may utilize PADI4 as a
cofactor to mediate their transactivation functions, thus suggesting
that the gene regulatory role for PADI4 is much broader than
previously thought. We also provide new mechanistic insights into
how PADI4 mediates gene transactivation by showing that PADI4
interacts with and citrullinates Elk-1 and that PADI4 enzymatic
activity potentiates two key features of c-Fos activation, Elk-1
phosphorylation and histone H4 acetylation. Studies are currently
underway to further dissect the mechanism by which PADI4
regulates gene expression and possibly mammary tumorigenesis.
Materials and Methods
Cell Culture and Constructs
MCF-7 cells were maintained in DMEM supplemented with 5%
calf serum and both HEK293 and JEG3 cells were maintained in
DMEM supplemented with 10% fetal bovine serum. Elk-1-depleted
MCF-7 and 293 cell lines were generated by transduction with
Mission Lentiviral Transduction Particles containing a short hairpin
RNA (shRNA) construct targeting the human Elk-1 coding
sequence (Sigma SHCLNV-NM_005229). In the control group,
cells were transduced with a non-targeting shRNA lentiviral
construct (Sigma SHC002V). Cells were selected by medium
containing 1 mg/ml puromycin (Sigma). PADI4-depleted MCF-7
cells were generated by transfection with Mission shRNA Plasmid
DNA targeting the human PADI4 coding sequence (Sigma
SHCLND-NM_012387). Control cells harboring a non-targeting
shRNA lentiviral construct (Sigma SHC002V) were generated in
parallel. PADI4 overexpression MCF-7 cells were generated by
transfection with PADI4-pcDNA3.1(+) and selected by medium
containing 500 mg/ml G418 (Gibco). Where indicated, Cl-Amidine
was diluted in cell culture medium at the final concentration of
200 mM and added to cells for 40 hr prior to harvest. Where
indicated, cells were serum starved for 12 hr (expression analysis) or
2 hr (ChIP assay) and subsequently stimulated with 50 ng/ml EGF
for 30 min. When required, cells were pre-treated with MAP kinase
inhibitor U0126 (10 mM) for 30 min before EGF stimulation.
Chromatin Immunoprecipitation (ChIP) and ChIP-Chip
ChIP was performed essentially as described previously [26].
MCF-7 cells were grown to ,80 to 90% confluence, cross-linked
with 1% paraformaldehyde for 10 min at 37uC, and quenched in
125 mM glycine. Cell lysates were sonicated under conditions
Figure 7. Working model depicting role of PADI4 in Elk-1–
mediated activation of c-Fos. (A) Prior to stimulation, Elk-1, PADI4,
and p300 constitutively occupy the c-Fos promoter. (B) Following EGF
treatment, Elk-1 is citrullinated by PADI4. (C) Upon citrullination, Elk-1 is
then phosphorylated by ERK2. (D) This phosphorylation event leads to
an enhanced interaction between Elk-1 and p300 (9). (E) The enhanced
interaction then potentiates p300-mediated histone acetylation and
subsequent transcriptional activation.
doi:10.1371/journal.pgen.1002112.g007
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yielding fragments ranging from 200 bp to 800 bp. The material
was clarified by centrifugation, diluted 10-fold in dilution buffer,
and pre-cleared with protein A-agarose beads. The pre-cleared,
chromatin-containing supernatant was used in immunoprecipita-
tion reactions with antibodies against PADI4 (Sigma P4749), Elk-1
(Santa Cruz sc-22804), p-Elk-1 (Santa Cruz sc-135646), Ac-H4K5
(Upstate 07-327), normal rabbit IgG (Upstate 12-370) or without
antibodies as a control. Ten percent of the supernatant was saved
as reference control. Both the immunoprecipitated genomic DNA
and the control DNA were cleared of protein and residual RNA by
digestion with proteinase K and RNase (Roche), respectively. The
DNA was then extracted with phenol:chloroform:isoamyl alcohol
and precipitated with ethanol. For gene-specific ChIP analyses,
quantitative real-time PCR (qPCR) was used to determine the
enrichment of immunoprecipitated DNA relative to the input
DNA using gene-specific primer sets to the specified regions. Each
ChIP experiment was conducted a minimum of three times with
independent chromatin isolates to ensure reproducibility. For the
ChIP-chip analyses, ChIP was performed in MCF-7 cells stripped
in MEM plus 5% charcoal-dextran-treated calf serum for 72 hrs.
LM-PCR-amplified immunoprecipitated DNA and the reference
DNA were hybridized to a human HG18 RefSeq promoter
microarray from Nimblegen. The array contained all known well-
characterized RefSeq gene promoters. The promoter region on
this array was covered by 50–75 mer probes with a mean probe
spacing of 100 bp. The detailed information is available on
Nimblegen’s website.
Genomic Data Analyses
The genomic data analyses were performed using the statistical
programming language R [47] essentially as described previously
[21]. All data processing scripts are available upon request. The
log2 ratio data from each array was subjected to lowess
normalization [48]. The normalized data were scaled to
equivalent sum of squares and then the between array mean
log2 ratio was determined for each probe. An error model was
generated using a 1 kb moving window with 250 bp steps in which
both the mean probe log2 ratio and p-values were calculated for
each window. The p-values were calculated using the nonpara-
metric Wilcoxon signed-rank test. The TSS-anchored ChIP-chip
heat maps were generated using 600 pb windows with 150 bp
steps and were visualized (Figure 1B) with Java Treeview [49]. For
genes with multiple TSSs, the most 59 site was used. The raw and
processed data from the ChIP-chip data described in this
manuscript can be found on the GEO website (http://www.
ncbi.nlm.nih.gov/geo/) using accession number GSE18755.
Identification of PADI4-bound and PADI4-unbound re-
gions. Significant PADI4 peaks were defined as the center of
three consecutive windows with positive means, at least six probes,
the center window with a mean greater than either adjacent
window, and all windows having p-values less than 0.016.
Significant PADI4 troughs were defined as the center of three
consecutive windows with negative means, at least six probes, the
center window with a mean less than either adjacent window,
and all windows having p-values less than 0.016. The use of
these selection criteria were justified by a low FPR as deter-
mined by ChIP-qPCR (PADI4-peak FPR,15%; PADI4-trough
FPR,15%).
Peak to TSS distances. The distance of PADI4 bound region
to the closest TSS (Figure 1B) was determined using RefSeq gene
annotations from the UCSC genome browser. A Fisher exact test
was used to determine the significance of the patterns observed in
the boundary histograms, comparing to the background pattern
obtained by determining the distance of all windows with at least six
probes to the closest TSS.
Expression-based classification of genes. For the expression-
based categorization of genes, three replicates of previously described
MCF-7 expression microarray data (Affymetrix U133A, GEO
accession number GSE9253) were associated with the genes re-
presented on the ChIP-chip array [26]. In cases where multiple probe
sets corresponded to a given gene, all signals from the probe sets were
averaged. For a gene on the ChIP-chip array to be marked as
unambiguously expressed or unexpressed, all probe sets from all three
expression array replicates corresponding to the gene must have been
flagged unanimously present or absent, respectively. Any genes on the
array not meeting these criteria were marked as ambiguous and were
removed from the expression based categorization analysis.
Multiple ChIP-chip correlation analysis. Data series con-
taining MCF-7 ChIP-chip data were downloaded from the Gene
Expression Omnibus (GEO) website (http://www.ncbi.nlm.nih.gov/
geo). The genomic data from the chosen series had to have been
performed using a two-color platform (i.e. Nimblegen, Agelent). In
total 362 ChIP-chip data sets from the following GEO series were
included in the analysis: GSE1778, GSE2072, GSE6292, GSE7118,
GSE8887, GSE2672, GSE4355, GSE4355, GSE10504, GSE3505,
GSE5175, GSE6625, GSE8667, GSE12126, GSE6624, GSE6634,
GSE8716, GSE12126, GSE5445, GSE9015, GSE12650, GSE5559,
GSE8716, GSE6385, GSE8855, GSE9029, GSE2672, GSE5559,
GSE13051. The data was processed with 1 kb windows identical to
that of the PADI4 analysis. The spearman correlation between PADI4
and each of the downloaded ChIP-chip data sets was then determined.
The score of each correlation was defined as the negative of the log10 of
the p-value for the correlation.
Comparion of PADI4 ChIP-chip with Elk-1 ChIP-chip. In
order to determine the enrichment of PADI4 at bona fide Elk-1
binding sites, Elk-1 peaks determined from Elk-1 ChIP-chip
experiment were obtained from previously published sources [33].
The ChIP-chip data was filtered for regions of the genome covered
by the PADI4 ChIP-chip array. An Elk-1 binding site was defined
as co-occupied by PADI4 if it occurred within 1.5 kb of a PADI4
peak. A Fisher exact test was used to determine the significance of
the enrichment of Elk-1binding sites near PADI4 peaks.
Enrichment of transcription factor binding sites (TFBS)
analysis. In order to determine which TFBS were enriched near
genes marked by PADI4 bound we used the conserved TFBS track
in the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/
hgTables) [50,51]. The training set for this analysis was composed of
all DNA within 2 kb of a TSS that contained a PADI4 binding
region. The background set was created by removing the training
set from the DNA within 2 kb of all TSS represented on the ChIP-
chip array. We used the functions of the Galaxy web site (http://
main.g2.bx.psu.edu/root) to determine the instances of TFBS in
both the background and training sets. The total number of bp
marked by each specific TFBS in both the background and training
sets was computed. This information was used to compute a p-value
for the enrichment using the Fisher exact test. Sequence Logos for
the 21 most enriched motifs presented in Figure 3A were generated
by using the position weight matrices from the Transfac database
(http://www.gene-regulation.com/pub/databases.html) and the R
package, SeqLogo [52].
Functional classification and annotation of the candidate
genes. The functional profiling of PADI4-assocaited transactive
genes was performed using the DAVID Bioinformatics Resources
6.7 [53,54]. 516 unambiguously expressed genes as having
significant PADI4 peaks were uploaded into DAVID and the
‘functional annotation tool’ was used to identify enriched
biological themes.
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Gene-Specific Expression Analyses
Total RNA was isolated from MCF-7 cells using Qiagen
RNeasy Mini Kit in combination with on-column DNase
treatment (ABI). High Capacity RNA-to-cDNA kit (ABI) was
used to synthesize the first strand of cDNA. Quantitative real-time
PCR (qPCR) was performed using Power SYBR Green PCR
Master Mix (ABI) with gene-specific primers. All target gene
transcripts were normalized to b-actin. PADI4 transcription in
PADI4-overexpressed MCF-7 cells was assessed using TaqMan
Gene Expression Master Mix (ABI) with Taqman probes and
primers (PADI4: Hs00202612_m1 and GAPDH: 4352934E, ABI).
Each experiment was conducted three times with independent
isolates of total RNA. The P-values were determined using a two-
tailed paired Student’s t-test. All of the primers used for the ChIP-
qPCR and RT-qPCR assays were listed in Table S3.
Small-Scale Chromatin Fractionation
PADI4-depleted and parallel control MCF-7 cells (90%
confluence in 10 cm culture plates) were collected, washed with
phosphate-buffered saline (PBS), and resuspended in 500 ml of
buffer A [10 mMHEPES (pH 7.9), 10 mM KCl, 1.5 mMMgCl2,
0.34 M sucrose, 10% glycerol, 1 mM dithiothreitol, and protease
inhibitor cocktail (Roche)]. Triton X-100 was added (0.1% final
concentration), the cells were incubated on ice for 8 min, and
nuclei were collected by centrifugation (5 min, 1,3006 g, 4uC).
The nuclei were washed once in buffer A and lysed for 30 min in
buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol, and
protease inhibitor cocktail), and insoluble chromatin and soluble
fractions were separated by centrifugation (5 min, 1,7006g, 4uC).
The chromatin fraction was washed once with buffer B and
resuspended in sodium dodecyl sulfate (SDS)-Laemmli buffer (and
boiled for 10 min) for Western Blot analysis.
Immunoprecipitation Assay
Flag-tagged PADI4 in pcDNA3.1 (+) or control vector were
transfected into 293 cells using FuGENE 6. The whole cell lysates
were immunoprecipitated with anti-Flag M2 affinity gel (Sigma
A2220) or immunoprecipitated with anti-Elk-1 antibody. Immu-
noprecipitates were washed and analysed by western blot using
anti-Elk-1, anti-phospho-Elk-1, and anti-PADI4 antibodies as
indicated.
Luciferase Reporter Assay
HEK293 cells were cotransfected using FuGENE 6 (Roche)
with 0.05 mg of c-Fos-luciferase construct containing the SRE
sequence as described previously [55], 0.25 mg of PADI4 (wild-
type [WT] or enzymatically inactive mutant, mutation of Cys645
into Ser645, [CS]) in pcDNA3.1(+), and 0.25 mg of Elk-1 (wild-type
[WT] or dominant-negative mutant, mutations of Ser383/Ser389
into Ala383/Ala389, [DN]) in pSG5 expression vectors [46]. For
GAL4-driven luciferase assay, expression vector for the DNA-
binding domain of GAL4 (CMV-GAL4) or GAL4-Elk-1 (full
length) was transfected into HEK293 cells with 5xGAL4-driven
luciferase reporter plasmid containing the minimal E1b promoter
and plasmids for pcDNA3.1, PADI4 WT and C645S mutant.
Lysates were assayed for luciferase activities 24 hours after
transfection according to the supplier’s protocol (Dual Luciferase,
Promega) and normalized to protein concentration in the extract.
PADI Assay and In Vitro ERK Kinase Assays
PADI4 proteins were expressed and purified from pET28b-
PADI4 or pET28b-PADI4 (C645S) mutant using Ni-NTA Pro-
tein Purification System (Qiagen) according to manufacturer’s
instructions. The PADI assay was performed essentially as
described previously [17]. The expressed Elk-1 was treated with
PADI4 in PADI buffer containing 50 mM Tris.HCl, pH 7.6,
4 mM DTT, 4 mM CaCl2 at 37uC for 1 hr. The mutant PADI4
(CS) was used as the negative control. Coupled in vitro
transcription/translations were performed from Elk-1 constructs
using the TNT-coupled reticulocyte lysate system (Promega) with
T7 RNA polymerase according to the instructions of the
manufacturer. Both wild-type (WT) and dominant-negative (DN)
Elk-1 cDNAs are in pSG5 expression vectors [46]. The In vitro
ERK kinase assay was performed as described previously [55].
Briefly, after EGF treatment, JEG3 cells (The cell line is highly
sensitive to EGF and has been shown to be good source for
activated ERKs [56]) were washed in 1 ml of ice-cold PBS and
lysed in radioimmune precipitation buffer containing 20 mM Tris
(pH 8.0), 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 0.1%
SDS, 0.5% deoxycholate, 2 mM EDTA, 5 mM sodium vanadate,
5 mM benzamidine, and 1 mM PMSF on ice for 10 min. The cell
lysates were collected and cleared by centrifugation. ERK2 was
immunoprecipitated by adding anti-ERK2 antibody (Santa Cruz
sc-154) and 25 ml of protein A/G-agarose beads to clarified cell
lysates. The beads were washed once in 1 ml of radioimmune
precipitation buffer; twice in 1 ml of ice-cold Nonidet P-40 wash
buffer; and once in 1 ml of kinase buffer containing 20 mM
HEPES (pH 7.5), 20 mM MgCl2, 25 mM b-glycerol phosphate,
100 mM sodium vanadate, 20 mMATP, and 2 mM dithiothreitol.
The reaction mixture (50 ml) contained the agarose beads
suspended in kinase buffer, and substrate Elk-1 pretreated with
PADI4. Samples were incubated for 30 min at 30uC with frequent
mixing and the reaction was terminated with the addition of SDS
loading buffer and boiled for 2 min, and analysed by western blot
using anti-phospho-Elk-1 (p-Elk-1), anti-Elk-1, anti-phospho-ERK
(p-ERK) (Cell Signalling E10), and anti-ERK2 antibodies as
indicated.
Supporting Information
Figure S1 PADI4 antibody specificity. (A) N-terminal amino
acid alignment (1–15) for PADI family members. Conserved
amino acids are denoted in red while amino acids conserved only
between certain family members are shown in blue (http://
bioinfo.genotoul.fr/multalin/multalin.html). (B) Western blot of
MCF-7 cell extracts following transfection of either pcDNA3.1 (+)
alone or pcDNA3.1 containing the flag-tagged PADI4 plasmid.
The PADI4-Flag fusion protein was detected using either an anti-
PADI4 antibody or an anti-Flag antibody. (C) MCF-7 cells were
transfected with empty vector, pcDNA3.1 (+), or with vectors
encoding different PADI family members. Immunoblots were
performed using anti-PADI1 (Abcam ab24008), PADI2 (Protein-
tech 12110-1-AP), PADI3 (Abcam ab50246), and PADI4 (Sigma
P4749) antibodies, respectively.
(DOC)
Figure S2 PADI4 is associated with known PADI4 bound gene
promoters (OKL38 and p21). ChIP-qPCR analysis of PADI4
binding at OKL38 promoter, and two p53-binding sites on the p21
gene promoter (PBS1 and PBS2) in MCF-7 cells.
(DOC)
Figure S3 Scatterplot showing the PADI4 ChIP-chip false
positive rate for both PADI4 peaks and troughs (,15% with
window P-value,0.016, respectively) as determined by ChIP-
qPCR. The detection threshold for PADI4 peak identification is
indicated by line.
(DOC)
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Figure S4 Putative consensus sequence for each transcription
factor. The top 21 motifs are listed in order of significance
according to Figure 3A. Sequence logo images were created using
the position weight matrices from the Transfac database (http://
www.gene-regulation.com/pub/databases.html) and the R pack-
age, SeqLogo.
(DOC)
Figure S5 Western Blot with anti-Elk-1 antibody showing
shRNA-mediated depletion of Elk-1 in HEK293 cells versus
shRNA control knockdown cells. b-Actin was used as internal
control showing the equal protein loading.
(DOC)
Figure S6 Dose-dependent effect of Cl-Amidine on c-Fos
expression. Real-time RT-PCR analysis of c-Fos and GAPDH
expression in serum-starved or EGF-stimulated MCF-7 cells with
or without Cl-Amidine treatment.
(DOC)
Figure S7 EGF-induced c-Fos gene expression is inhibited by Cl-
Amidine treatment in other breast cancer cells. Real-time RT-
PCR analysis of c-Fos expression in serum-starved or EGF-
stimulated BT474 and MCF10DCIS breast cancer cells with or
without Cl-Amidine treatment.
(DOC)
Figure S8 Luciferase reporter assay with construct driven by the
c-Fos promoter in HEK293 cells showing that PADI4 enzymatic
activity facilitates Elk-1 mediated activation of c-Fos. Either wild
type (WT) or C645S mutant (CS) PADI4 with N-terminal Flag tag
and either wild type (WT) or dominant negative (DN) Elk-1 with
N-terminal HA tag were co-transfected with the c-Fos reporter
construct (c-Fos promoter fragment containing 531 nucleotides
which begins 85 nucleotides downstream from the TATAA box
and contains 446 nucleotides upstream of the TATAA box. SRE
sequence was included in this construct). Empty vector was used to
normalize the equal amount of plasmid DNA transfected.
Luciferase activity was measured as described in Figure 4F. In
the lower panel, the expressions of Flag-PADI4 and HA-Elk-1
fusion proteins were monitored by western lot using anti-Flag and
anti-HA antibodies.
(DOC)
Table S1 PADI4 binding regions identified by ChIP-chip
analysis (P-value,0.016). See separate Excel file.
(XLS)
Table S2 Gene ontology analysis for the transactive genes
associated with PADI4 binding in MCF-7 cells. See separate Excel
file.
(XLS)
Table S3 Details of PCR primers used for the ChIP-qPCR and
RT-qPCR assays.
(DOC)
Acknowledgments
We are grateful to Dr. Richard Treisman (Cancer Research UK, London
Research Institute) and Dr. Jocelyne Caboche (Universite´ Pierre et Marie
Curie-Paris 6), who kindly provided us the wild-type and dominant-
negative Elk-1 plasmids. We thank Dr. Raga Krishnakumar for technical
advice and helpful discussions.
Author Contributions
Conceived and designed the experiments: XZ MJG MSR WLK SAC.
Performed the experiments: XZ BDC. Analyzed the data: XZ MJG MSR
WLK SAC. Contributed reagents/materials/analysis tools: SS CPC PRT
MSR. Wrote the paper: XZ SAC.
References
1. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A (1991) Ets-related
protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. Nature 354:
531–534.
2. Treisman R (1990) The SRE: a growth factor responsive transcriptional
regulator. Semin Cancer Biol 1: 47–58.
3. Hill CS, Wynne J, Treisman R (1994) Serum-regulated transcription by serum
response factor (SRF): a novel role for the DNA binding domain. EMBO J 13:
5421–5432.
4. Hill CS, Treisman R (1995) Transcriptional regulation by extracellular signals:
mechanisms and specificity. Cell 80: 199–211.
5. Price MA, Rogers AE, Treisman R (1995) Comparative analysis of the ternary
complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J 14:
2589–2601.
6. Liao J, Hodge C, Meyer D, Ho PS, Rosenspire K, et al. (1997) Growth hormone
regulates ternary complex factors and serum response factor associated with the
c-fos serum response element. J Biol Chem 272: 25951–25958.
7. Treisman R (1985) Transient accumulation of c-fos RNA following serum
stimulation requires a conserved 59 element and c-fos 39 sequences. Cell 42:
889–902.
8. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, et al. (1995)
ERK phosphorylation potentiates Elk-1-mediated ternary complex formation
and transactivation. EMBO J 14: 951–962.
9. Li QJ, Yang SH, Maeda Y, Sladek FM, Sharrocks AD, et al. (2003) MAP kinase
phosphorylation-dependent activation of Elk-1 leads to activation of the co-
activator p300. EMBO J 22: 281–291.
10. Janknecht R, Ernst WH, Pingoud V, Nordheim A (1993) Activation of ternary
complex factor Elk-1 by MAP kinases. EMBO J 12: 5097–5104.
11. Hodge C, Liao J, Stofega M, Guan K, Carter-Su C, et al. (1998) Growth
hormone stimulates phosphorylation and activation of elk-1 and expression of c-
fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1
and 2. J Biol Chem 273: 31327–31336.
12. Li B, Carey M, Workman JL (2007) The role of chromatin during transcription.
Cell 128: 707–719.
13. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:
693–705.
14. O’Donnell A, Yang SH, Sharrocks AD (2008) MAP kinase-mediated c-fos
regulation relies on a histone acetylation relay switch. Mol Cell 29: 780–785.
15. Hagiwara T, Nakashima K, Hirano H, Senshu T, Yamada M (2002)
Deimination of arginine residues in nucleophosmin/B23 and histones in HL-
60 granulocytes. Biochem Biophys Res Commun 290: 979–983.
16. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T,
et al. (2004) Histone deimination antagonizes arginine methylation. Cell 118:
545–553.
17. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, et al. (2004) Human PAD4
regulates histone arginine methylation levels via demethylimination. Science
306: 279–283.
18. Denis H, Deplus R, Putmans P, Yamada M, Me´tivier R, et al. (2009) Functional
connection between deimination and deacetylation of histones. Mol Cell Biol 29:
4982–4993.
19. Li P, Yao H, Zhang Z, Li M, Luo Y, et al. (2008) Regulation of p53 target gene
expression by peptidylarginine deiminase 4. Mol Cell Biol 28: 4745–4758.
20. Yao H, Li P, Venters BJ, Zheng S, Thompson PR, et al. (2008) Histone Arg
modifications and p53 regulate the expression of OKL38, a mediator of
apoptosis. J Biol Chem 283: 20060–20068.
21. Gamble MJ, Frizzell KM, Yang C, Krishnakumar R, Kraus WL (2010) The
histone variant macroH2A1 marks repressed autosomal chromatin, but protects
a subset of its target genes from silencing. Genes Dev 24: 21–32.
22. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide
analysis of estrogen receptor binding sites. Nat Genet 38: 1289–1297.
23. Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, et al. (2007) Genomic
analyses of transcription factor binding, histone acetylation, and gene expression
reveal mechanistically distinct classes of estrogen-regulated promoters. Mol Cell
Biol 27: 5090–5104.
24. Xu X, Bieda M, Jin VX, Rabinovich A, Oberley MJ, et al. (2007) A
comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and
tumor cells reveals interchangeable roles of E2F family members. Genome Res
17: 1550–1561.
25. Rabinovich A, Jin VX, Rabinovich R, Xu X, Farnham PJ (2008) E2F in vivo
binding specificity: comparison of consensus versus nonconsensus binding sites.
Genome Res 18: 1763–1777.
26. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, et al.
(2008) Reciprocal binding of PARP-1 and histone H1 at promoters specifies
transcriptional outcomes. Science 319: 819–821.
27. Ge´vry N, Hardy S, Jacques PE, Laflamme L, Svotelis A, et al. (2009) Histone
H2A.Z is essential for estrogen receptor signaling. Genes Dev 23: 1522–1533.
PADI4 and Gene Regulation
PLoS Genetics | www.plosgenetics.org 14 June 2011 | Volume 7 | Issue 6 | e1002112
28. Lachner M, O’Sullivan RJ, Jenuwein T (2003) An epigenetic road map for
histone lysine methylation. J Cell Sci 116: 2117–2124.
29. Komashko VM, Acevedo LG, Squazzo SL, Iyengar SS, Rabinovich A, et al.
(2008) Using ChIP-chip technology to reveal common principles of transcrip-
tional repression in normal and cancer cells. Genome Res 18: 521–532.
30. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ (2007) Genome-wide analyses
reveal properties of redundant and specific promoter occupancy within the ETS
gene family. Genes Dev 21: 1882–1894.
31. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, et al.
(2009) DNA specificity determinants associate with distinct transcription factor
functions. PLoS Genet 5: e1000778. doi:10.1371/journal.pgen.1000778.
32. Collins PJ, Kobayashi Y, Nguyen L, Trinklein ND, Myers RM (2007) The ets-
related transcription factor GABP directs bidirectional transcription. PLoS
Genet 3: e208. doi:10.1371/journal.pgen.0030208.
33. Boros J, Donaldson IJ, O’Donnell A, Odrowaz ZA, Zeef L, et al. (2009)
Elucidation of the ELK1 target gene network reveals a role in the coordinate
regulation of core components of the gene regulation machinery. Genome Res
19: 1963–1973.
34. Treisman R, Marais R, Wynne J (1992) Spatial flexibility in ternary complexes
between SRF and its accessory proteins. EMBO J 11: 4631–4640.
35. Wilding G, Lippman ME, Gelmann EP (1988) Effects of steroid hormones and
peptide growth factors on protooncogene c-fos expression in human breast
cancer cells. Cancer Res 48: 802–805.
36. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, et al. (2006) Inhibitors and
inactivators of protein arginine deiminase 4: functional and structural
characterization. Biochemistry 45: 11727–11736.
37. Li Q, Vaingankar SM, Green HM, Martins-Green M (1999) Activation of the
9E3/cCAF chemokine by phorbol esters occurs via multiple signal transduction
pathways that converge to MEK1/ERK2 and activate the Elk1 transcription
factor. J Biol Chem 274: 15454–15465.
38. Senshu T, Sato T, Inoue T, Akiyama K, Asaga H (1992) Detection of citrulline
residues in deiminated proteins on polyvinylidene difluoride membrane. Anal
Biochem 203: 94–100.
39. Stuart ET, Gruss P (1996) PAX: developmental control genes in cell growth and
differentiation. Cell Growth Differ 7: 405–412.
40. Delannoy-Courdent A, Mattot V, Fafeur V, Fauquette W, Pollet I, et al. (1998)
The expression of an Ets1 transcription factor lacking its activation domain
decreases uPA proteolytic activity and cell motility, and impairs normal
tubulogenesis and cancerous scattering in mammary epithelial cells. J Cell Sci
111: 1521–1534.
41. Levy DE, Gilliland DG (2000) Divergent roles of STAT1 and STAT5 in
malignancy as revealed by gene disruptions in mice. Oncogene 19: 2505–2510.
42. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, et al. (2000) E2F-1: a
proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9:
395–401.
43. Clevenger CV (2004) Roles and regulation of stat family transcription factors in
human breast cancer. Am J Pathol 165: 1449–1460.
44. Robson EJ, He SJ, Eccles MR (2006) A PANorama of PAX genes in cancer and
development. Nat Rev Cancer 6: 52–62.
45. Lee YH, Coonrod SA, Kraus WL, Jelinek MA, Stallcup MR (2005) Regulation
of coactivator complex assembly and function by protein arginine methylation
and demethylimination. Proc Natl Acad Sci USA 102: 3611–3616.
46. Vanhoutte P, Nissen JL, Brugg B, Gaspera BD, Besson MJ, et al. (2001)
Opposing roles of Elk-1 and its brain-specific isoform, short Elk-1, in nerve
growth factor-induced PC12 differentiation. J Biol Chem 276: 5189–5196.
47. R Development Core Team (2006) R. A language and environment for
statistical computing. In. R Foundation for Statistical Computing, Vienna,
Austria.
48. Smyth GK, Speed T (2003) Normalization of cDNA microarray data. Methods
31: 265–273.
49. Saldanha AJ (2004) Java Treeview–extensible visualization of microarray data.
Bioinformatics 20: 3246–3248.
50. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, et al. (2004) The
UCSC Table Browser data retrieval tool. Nucleic Acids Res 32: 493–496.
51. Kuhn RM, Karolchik D, Zweig AS, Wang T, Smith KE, et al. (2009) The
UCSC Genome Browser Database: update 2009. Nucleic Acids Res 37:
755–761.
52. Bembom O (2008) seqLogo: Sequence logos for DNA sequence alignments.
R package version 1.12.0.
53. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
4: P3.
54. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID Bioinformatics Resources. Nature
Protoc 4: 44–57.
55. Roberson MS, Zhang T, Li HL, Mulvaney JM (1999) Activation of the p38
mitogen-activated protein kinase pathway by gonadotropin-releasing hormone.
Endocrinology 140: 1310–1318.
56. Roberson MS, Ban M, Zhang T, Mulvaney JM (2000) Role of the cyclic AMP
response element binding complex and activation of mitogen-activated protein
kinases in synergistic activation of the glycoprotein hormone alpha subunit gene
by epidermal growth factor and forskolin. Mol Cell Biol 20: 3331–3344.
PADI4 and Gene Regulation
PLoS Genetics | www.plosgenetics.org 15 June 2011 | Volume 7 | Issue 6 | e1002112
